Latest Views & News

Tizania to dump its AIM quote - mea culpa

By Malcolm Stacey | Monday 13 January 2020

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Hello Share Mates. Last week I commended a medical pioneer to your attention because it had just announced exciting news. The Nasdaq and AIM-listed Tiziana (TILS)was given an encouraging boost by the Harvard Medical School no less for a positive test for its Foralumab drug for boosting the immune system.

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was